255 related articles for article (PubMed ID: 29624746)
61. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.
Griffiths EA; Gore SD; Hooker CM; Mohammad HP; McDevitt MA; Smith BD; Karp JE; Herman JG; Carraway HE
Epigenetics; 2010 Oct; 5(7):590-600. PubMed ID: 20671427
[TBL] [Abstract][Full Text] [Related]
62. High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy.
Qin YZ; Zhao T; Zhu HH; Wang J; Jia JS; Lai YY; Zhao XS; Shi HX; Liu YR; Jiang H; Huang XJ; Jiang Q
Med Sci Monit; 2018 Feb; 24():758-767. PubMed ID: 29408852
[TBL] [Abstract][Full Text] [Related]
63. Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
Mizushima Y; Taki T; Shimada A; Yui Y; Hiraumi Y; Matsubara H; Watanabe M; Watanabe K; Kamitsuji Y; Hayashi Y; Tsukimoto I; Kobayashi R; Horibe K; Tawa A; Nakahata T; Adachi S
Int J Hematol; 2010 Jun; 91(5):831-7. PubMed ID: 20495894
[TBL] [Abstract][Full Text] [Related]
64. Therapeutic advances in acute myeloid leukemia.
Burnett A; Wetzler M; Löwenberg B
J Clin Oncol; 2011 Feb; 29(5):487-94. PubMed ID: 21220605
[TBL] [Abstract][Full Text] [Related]
65. Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission.
Yanada M; Kurosawa S; Yamaguchi T; Yamashita T; Moriuchi Y; Ago H; Takeuchi J; Nakamae H; Taguchi J; Sakura T; Takamatsu Y; Waki F; Yokoyama H; Watanabe M; Emi N; Fukuda T
Haematologica; 2012 Jun; 97(6):915-8. PubMed ID: 22180431
[TBL] [Abstract][Full Text] [Related]
66. Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Papaemmanuil E; Gerstung M; Bullinger L; Gaidzik VI; Paschka P; Roberts ND; Potter NE; Heuser M; Thol F; Bolli N; Gundem G; Van Loo P; Martincorena I; Ganly P; Mudie L; McLaren S; O'Meara S; Raine K; Jones DR; Teague JW; Butler AP; Greaves MF; Ganser A; Döhner K; Schlenk RF; Döhner H; Campbell PJ
N Engl J Med; 2016 Jun; 374(23):2209-2221. PubMed ID: 27276561
[TBL] [Abstract][Full Text] [Related]
67. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
Mrózek K; Marcucci G; Nicolet D; Maharry KS; Becker H; Whitman SP; Metzeler KH; Schwind S; Wu YZ; Kohlschmidt J; Pettenati MJ; Heerema NA; Block AW; Patil SR; Baer MR; Kolitz JE; Moore JO; Carroll AJ; Stone RM; Larson RA; Bloomfield CD
J Clin Oncol; 2012 Dec; 30(36):4515-23. PubMed ID: 22987078
[TBL] [Abstract][Full Text] [Related]
68. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study.
Kosmider O; Delabesse E; de Mas VM; Cornillet-Lefebvre P; Blanchet O; Delmer A; Recher C; Raynaud S; Bouscary D; Viguié F; Lacombe C; Bernard OA; Ifrah N; Dreyfus F; Fontenay M;
Haematologica; 2011 Jul; 96(7):1059-63. PubMed ID: 21508122
[TBL] [Abstract][Full Text] [Related]
69. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
LaRochelle O; Bertoli S; Vergez F; Sarry JE; Mansat-De Mas V; Dobbelstein S; Dastugue N; Strzelecki AC; Cavelier C; Creancier L; Pillon A; Kruczynski A; Demur C; Sarry A; Huguet F; Huynh A; Récher C; Delabesse E
Oncotarget; 2011 Nov; 2(11):850-61. PubMed ID: 22081665
[TBL] [Abstract][Full Text] [Related]
70. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
[TBL] [Abstract][Full Text] [Related]
71. Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution.
Nahi H; Remberger M; Machaczka M; Ungerstedt J; Mattson J; Ringden O; Le-Blanc K; Ljungman P; Hägglund H
Med Oncol; 2012 Dec; 29(4):2348-58. PubMed ID: 22234457
[TBL] [Abstract][Full Text] [Related]
72. Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia.
Larson RA
Chem Biol Interact; 2010 Mar; 184(1-2):21-5. PubMed ID: 19822134
[TBL] [Abstract][Full Text] [Related]
73. Demethylator phenotypes in acute myeloid leukemia.
Kelly AD; Madzo J; Madireddi P; Kropf P; Good CR; Jelinek J; Issa JJ
Leukemia; 2018 Oct; 32(10):2178-2188. PubMed ID: 29556023
[TBL] [Abstract][Full Text] [Related]
74. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.
Pabst T; Eyholzer M; Fos J; Mueller BU
Br J Cancer; 2009 Apr; 100(8):1343-6. PubMed ID: 19277035
[TBL] [Abstract][Full Text] [Related]
75. [The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients].
Wei JF; Chen GH; Qiu HY; Fu CC; Ding ZX; Liu H; Feng YF; Chen SN; Chang WR; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):304-7. PubMed ID: 21729597
[TBL] [Abstract][Full Text] [Related]
76. Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single-center experience.
Davis KL; Marina N; Arber DA; Ma L; Cherry A; Dahl GV; Heerema-McKenney A
Am J Clin Pathol; 2013 Jun; 139(6):818-25. PubMed ID: 23690127
[TBL] [Abstract][Full Text] [Related]
77. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?
Odenike O; Thirman MJ; Artz AS; Godley LA; Larson RA; Stock W
Semin Oncol; 2011 Apr; 38(2):196-214. PubMed ID: 21421110
[TBL] [Abstract][Full Text] [Related]
78. Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment.
Rautenberg C; Germing U; Haas R; Kobbe G; Schroeder T
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626126
[TBL] [Abstract][Full Text] [Related]
79. Extramedullary infiltration in pediatric acute myeloid leukemia: Results from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative.
Li W; Shi M; Zhou P; Liu Y; Liu X; Xiao X; Zuo S; Bai Y; Sun K
Pediatr Blood Cancer; 2024 Jul; 71(7):e31014. PubMed ID: 38644612
[TBL] [Abstract][Full Text] [Related]
80. Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.
Quintana-Bustamante O; Lan-Lan Smith S; Griessinger E; Reyal Y; Vargaftig J; Lister TA; Fitzgibbon J; Bonnet D
Leukemia; 2012 Jul; 26(7):1537-46. PubMed ID: 22371011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
